Tasmanian salmon farmers seek florfenicol permit as AMA urges wider health review

Tasmanian salmon farmers seek florfenicol permit as AMA urges wider health review
Salmon farmers seek review

Tasmania's salmon industry is awaiting a regulatory decision on renewed access to the antibiotic florfenicol after disease outbreaks drove heavy fish losses and earlier emergency use. The Australian Medical Association says the assessment should weigh antimicrobial resistance, environmental exposure and potential trade implications before any new permit is approved.

Highlights

  • Australian Pesticides and Veterinary Medicines Authority is reviewing Salmon Tasmania's emergency permit request to use florfenicol again, with a decision expected as early as this week.
  • Australian Medical Association urges full, independent human health and environmental risk assessments on florfenicol, citing potential antimicrobial resistance, and criticizes repeated emergency permits.
  • Tasmania's Environment Department closed commercial rock lobster and dive fisheries in parts of the southeast for three months to manage trade risks from antibiotic use in salmon farming, impacting broader sector stakeholders.

Permit review and health concerns

As reported by ABC News, the Australian Pesticides and Veterinary Medicines Authority is assessing an emergency application from Salmon Tasmania to allow florfenicol to be used again in Tasmanian waterways, after public submissions closed on November 16 and a decision is expected as early as this coming week.

The Australian Medical Association says antimicrobial resistance is one of the most serious global health threats of the 21st century and argues the regulator should consider human health and environmental risks alongside animal treatment needs. In its submission, the group says the consequences for public health, the environment and market access may be underestimated, and that health and trade cannot be separated.

Florfenicol was first used in the state's south-eastern waters in November last year after the regulator approved an emergency permit in response to a bacterial disease that killed 15,000 tonnes of salmon in early 2025. The authority revoked that permit in March this year, citing an unacceptable risk of residue exposure to non-target species after traces were detected in wild fish up to 10 kilometres from the nearest treated salmon pen and later in abalone up to 14 kilometres away.

The AMA is urging the agency to require a full assessment rather than repeated emergency permits, with independent environmental and human health risk evaluations made public. It says a review should examine whether resistant bacteria and resistance genes could reach people through water, seafood and occupational contact, while noting it is not arguing that this use will inevitably produce unacceptable resistance.

Industry response and broader sector impact

Salmon Tasmania chief executive John Whittington says the industry agrees antimicrobial resistance is a serious global issue, but maintains antibiotics are not used routinely or preventatively in Tasmanian salmon farming. He says vaccination and selective breeding are the first line of defence, and that antibiotics are used only to treat diagnosed disease under veterinary prescription.

Whittington says much of the work sought by the AMA is already in place or underway, including sample collection and a research program developed with IMAS and the EPA on antibiotic resistance genes in the marine environment. He also says florfenicol is not used to treat human infections in Australia, and cites public health advice that there is no evidence of harm to human health from consuming traces of the antibiotic.

The Tasmanian Health Department has previously said there are no reports of adverse human health effects from eating seafood with florfenicol residues, while advising consumers who want to avoid possible exposure that they could avoid wild finfish caught within 3 kilometres of a treated lease for 21 days after treatment ends. The AMA counters that medicated feed in salmon pens cannot be fully contained and that aquatic workers, divers, fish processors, fishers and coastal communities may be exposed to resistant organisms.

The permit debate also carries commercial implications beyond salmon farming. Tasmania's Environment Department closed the commercial rock lobster and commercial dive fisheries in parts of the state's south-east for three months to mitigate trade risks linked to antibiotic use by the salmon industry, a move some affected fishers have criticised as unfair. Meanwhile, the regulator is separately considering a minor use permit application from Abbey Labs, which a Senate estimates hearing in October heard would cover higher florfenicol dose rates in the south-eastern and eastern biosecurity zones.

As a reminder, our earlier coverage of patented medicine sales in Canada highlighted the sector’s rising market share and pricing context.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.